Back HIV/AIDS HIV/AIDS Topics HIV Treatment

HIV11: Infants Who Start Antiretrovirals Early Keep HIV Suppressed Despite Treatment Interruption

Babies who started taking lopinavir-based antiretroviral therapy (ART) soon after they were diagnosed with HIV experienced good virological response that was sustained through 6 years, even after they stopped treatment, according to long-term data from the CHER study presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.alt

Read more:

HIV11: Dolutegravir Remains Effective for Treatment-experienced People with Multidrug-resistant HIV

The investigational HIV integrase inhibitor dolutegravir, which has shown comparable or superior efficacy to widely used drugs in clinical trials to date, works well for people with highly resistant HIV, including virus with mutations conferring resistance to other drugs in its class, researchers reported at the 11th International Congress on Drug Therapy in HIV Infection (HIV11) this week in Glasgow.alt

Read more:

Pegylated Interferon May Maintain HIV Suppression and Reduce Viral DNA Integration

Adding pegylated interferon alfa to antiretroviral therapy (ART) for HIV may help some people control viral replication when they interrupt treatment, according to a small study reported at this year's Conference on Retroviruses and Opportunistic Infections (CROI 2012) and published in the October 26, 2012, advance online edition of the Journal of Infectious Diseases.alt

Read more:

ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone

The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.alt

Read more:

Antiretroviral Treatment Lowers Risk of Non-AIDS Illness in People Newly Diagnosed with HIV

Non-AIDS conditions are a significant cause of illness and death for people recently diagnosed with HIV, but starting antiretroviral therapy (ART) can reduce the likelihood of non-AIDS events including psychiatric and kidney problems, according to study findings published in the September 26, 2012, advance online edition of AIDS.alt

Read more:

Many People with HIV Skip Antiretroviral Therapy When They Drink Alcohol

About half of people who both take antiretroviral therapy (ART) and drink alcohol reported that they sometimes skip medication doses while drinking, according to a cohort study described in the October 12, 2012, advance online edition of the Journal of General Internal Medicine.alt

Read more:

ICAAC 2012: New Tenofovir Pro-drug Matches Potency of Original Version but with Less Toxicity

Tenofovir alafenamide fumarate (TAF), the tenofovir pro-drug formerly known as GS-7340, has antiviral potency similar to that of tenofovir disoproxil fumarate (TDF), and a new "quad" formulation containing TAF works as well as the Stribild single-tablet regimen (elvitegravir/cobicistat/TDF/emtricitabine) but appears to be easier on the bones and kidneys, according to recently released data.alt

Read more: